Vyvanse vs Adderall XR: Cost and Access Head-to-Head

What Are Vyvanse and Adderall XR?

Vyvanse and Adderall XR are both extended-release amphetamine formulations approved by the FDA for ADHD, but their pharmacology differs in one meaningful way. Vyvanse is a prodrug: lisdexamfetamine is enzymatically cleaved in the gastrointestinal tract to release d-amphetamine, which makes intranasal or intravenous misuse less rewarding. Adderall XR delivers a 50/50 mix of immediate- and delayed-release beads of mixed amphetamine salts (75% d-amphetamine, 25% l-amphetamine).

Mechanism of Action

Both drugs work by increasing synaptic dopamine and norepinephrine through reuptake inhibition and reverse transport at the presynaptic terminal [1]. The net clinical effect, improved attention and reduced hyperactivity, is similar between the two agents at therapeutically equivalent doses.

FDA-Approved Indications

The FDA approved Vyvanse for ADHD in adults and children aged 6 and older, and separately for moderate-to-severe binge eating disorder (BED) in adults [2]. Adderall XR is FDA-approved for ADHD in children aged 6 and older and in adults, but carries no BED indication [3].

Prodrug Design and Abuse Potential

Vyvanse's prodrug design received considerable attention at approval. Because enzymatic cleavage is required, crushing or dissolving the capsule does not meaningfully accelerate the onset compared to swallowing it intact [4]. This characteristic does not eliminate misuse but may reduce the reinforcing pharmacokinetics associated with rapid amphetamine delivery.

Efficacy: What the Clinical Data Show

Neither drug has been tested head-to-head in a large randomized controlled trial with cost or access as an endpoint. What exists are well-powered independent efficacy trials and one manufacturer-sponsored crossover study.

Vyvanse Efficacy Evidence

Wigal et al. (J Atten Disord, 2017; N=142 adults) demonstrated that lisdexamfetamine produced sustained ADHD symptom reduction over a 12-to-13-hour observation window in an analog classroom setting, with statistically significant improvements in ADHD Rating Scale scores compared to placebo at every time point measured (P<0.001) [5]. The study used doses of 30 mg, 50 mg, and 70 mg.

A key registration trial (SPD489-325; N=420 adults) showed that lisdexamfetamine 30 to 70 mg reduced ADHD-RS-IV total scores by 16.2 to 17.5 points from baseline versus 8.2 points for placebo (P<0.001) [6].

Adderall XR Efficacy Evidence

The landmark MTA Cooperative Group study (Arch Gen Psychiatry, 1999; N=579 children aged 7 to 9) compared systematic stimulant management, behavioral therapy, combined treatment, and community care. Systematic medication management, which included mixed amphetamine salts for many participants, produced significantly greater ADHD symptom reduction than behavioral therapy alone or community care (P<0.001) [7]. At 14 months, combined treatment and medication-only arms showed comparable ADHD outcomes, both superior to behavioral therapy alone.

A separate placebo-controlled trial of Adderall XR in adults (N=255) showed mean ADHD-RS-IV reductions of 15.6 to 17.4 points at doses of 20 to 60 mg versus 7.7 points for placebo [8].

Side-by-Side Efficacy Summary

Neither agent shows a clinically meaningful efficacy advantage over the other at equivalent amphetamine doses [9]. The American Academy of Pediatrics' 2019 ADHD Clinical Practice Guideline states: "Stimulant medications have the most evidence for the treatment of ADHD and are considered the first-line pharmacological treatment in most cases." [10] Both Vyvanse and Adderall XR fall within that stimulant category.

Cost Comparison: The Numbers That Matter

Cost is where these two drugs diverge most sharply. Understanding the difference requires separating brand cost from generic cost, and cash price from insured price.

Brand-Name Pricing

Brand Vyvanse (Takeda) carries a wholesale acquisition cost (WAC) of approximately $382, $424 per month for a 30-capsule supply, depending on strength, as of early 2025. Brand Adderall XR (Shire/Takeda) is rarely dispensed now that generics exist, but its WAC is comparable when still stocked.

Most commercial insurance plans place both brand stimulants on Tier 3 or Tier 4, meaning typical out-of-pocket costs range from $60 to $150 per fill with insurance, before any deductible applies.

Generic Availability: The Key Dividing Line

Generic Adderall XR (mixed amphetamine salts extended-release) has been available since 2009. GoodRx cash prices for a 30-capsule supply of generic Adderall XR 20 mg typically run $30, $60 at major pharmacy chains [11].

Generic lisdexamfetamine (Vyvanse generic) received FDA approval and launched in August 2023 following Takeda's patent expiration. By early 2025, cash prices at GoodRx-participating pharmacies for a 30-capsule supply of generic lisdexamfetamine 40 mg run approximately $70, $130, still meaningfully higher than generic Adderall XR, though the gap has been narrowing as additional manufacturers enter the market [12].

Manufacturer Savings Programs

Takeda offers the Vyvanse Savings Card, which can reduce out-of-pocket brand costs to as low as $30/month for commercially insured patients. This program does not apply to Medicare, Medicaid, or uninsured patients paying cash.

No equivalent branded savings card exists for Adderall XR because the brand is largely discontinued; patients typically rely on generic pricing or pharmacy discount programs.

Insurance Formulary Considerations

Many Medicaid formularies and Medicare Part D plans cover generic Adderall XR at low or no cost-share under Tier 1 or Tier 2 placement. Generic lisdexamfetamine formulary placement varies by plan. Patients should verify tier status through their plan's formulary tool or by calling the plan's pharmacy benefits line before the prescriber writes the Rx.

Access and Availability: Shortages, Scheduling, and Telehealth Rules

The Adderall XR Shortage

The FDA placed Adderall (immediate-release) on the drug shortage list in October 2022, citing increased demand and manufacturing constraints [13]. Extended-release formulations, including generic Adderall XR, experienced related but separately tracked supply disruptions through 2023 and into 2024. Vyvanse experienced fewer reported shortage incidents during the same period, partly because lisdexamfetamine is manufactured by a smaller number of suppliers under tighter production controls.

DEA Schedule II Requirements

Both drugs are Schedule II controlled substances under the Controlled Substances Act. Federal law requires a new written or electronic prescription each calendar month; no refills are permitted on Schedule II prescriptions [14]. This rule applies identically to both drugs regardless of formulation.

Telehealth Prescribing: Post-COVID Rules

During the COVID-19 Public Health Emergency, the DEA issued waivers allowing telehealth providers to prescribe Schedule II stimulants without an in-person evaluation. Those waivers were extended through December 31, 2025 [15]. After that date, absent new rulemaking, a prior in-person visit may be required before a telehealth provider can initiate Vyvanse or Adderall XR. Patients currently receiving either drug via telehealth should confirm continuity of care with their provider well before the deadline.

Pharmacy Stock Variability

Because generic Adderall XR is manufactured by multiple companies (Amneal, Teva, Actavis/Allergan, and others), pharmacy stock varies by manufacturer lot. A patient whose prescription is written for "generic Adderall XR" may receive capsules from a different manufacturer each month, which some patients report as a perceived difference in effect (though bioequivalence standards require 80 to 125% AUC equivalence to the reference listed drug) [16]. Vyvanse generic currently has fewer approved manufacturers, which may mean more consistent supply per pharmacy but less total market stock.

Tolerability and Side Effects

Both drugs share a class-effect adverse event profile that is well characterized across decades of amphetamine research.

Shared Side Effects

Common adverse effects appearing in more than 5% of patients in key trials include decreased appetite, insomnia, dry mouth, headache, and elevated heart rate [17]. The FDA label for both drugs carries a boxed warning regarding the potential for abuse and dependence [2, 3].

Cardiovascular Considerations

Amphetamines raise mean blood pressure by approximately 2 to 4 mmHg and heart rate by 3 to 6 bpm at therapeutic doses based on pooled registration trial data [18]. The American Heart Association's 2008 scientific statement on cardiovascular monitoring in stimulant-treated children recommends baseline and follow-up blood pressure and heart rate measurements, a recommendation that extends logically to adults [19].

Onset and "Wearing Off"

Vyvanse reaches peak plasma d-amphetamine concentration (Tmax) approximately 3.8 hours post-dose. Adderall XR produces a bimodal plasma curve with peaks at approximately 1.5 and 6.5 hours, reflecting the bead-release design [20]. Clinically, some patients report a smoother offset with Vyvanse due to the slower build from prodrug conversion, while others prefer the faster initial onset of Adderall XR's first bead-release pulse. No randomized trial has quantified patient preference at population scale.

Who Should Consider Each Drug?

The decision between lisdexamfetamine and mixed amphetamine salts extended-release is less about which drug is more effective and more about individual patient circumstances. The table below maps four clinical scenarios to a preferred starting point.

| Clinical Scenario | Preferred Starting Agent | Rationale | |---|---|---| | No insurance, cash pay | Generic Adderall XR | ~$30, $60/month vs. ~$70, $130 for generic lisdexamfetamine | | History of stimulant misuse or diversion concern | Vyvanse (brand or generic) | Prodrug design reduces reinforcing rapid-onset pharmacokinetics | | Comorbid binge eating disorder | Vyvanse | Only stimulant with FDA approval for BED | | Prior Adderall XR failure at max dose | Trial lisdexamfetamine | Different prodrug kinetics may produce different subjective profile | | Medicare/Medicaid coverage, formulary Tier 1 | Generic Adderall XR | Broader formulary placement as of 2025 |

The Endocrine Society and AACE do not publish specific stimulant-selection guidance; prescriber judgment guided by patient history, formulary, and comorbidities drives the choice [21].

Switching from Vyvanse to Adderall XR (or Vice Versa)

Switching between these agents is common, typically driven by cost, shortage-related access, or inadequate response. No washout period is required because both drugs share the same active moiety (d-amphetamine) or closely related amphetamine salts and have short half-lives of 10 to 13 hours for d-amphetamine [22].

Dose Conversion Guidance

No published dose-equivalency table has been validated in a randomized trial for lisdexamfetamine to mixed amphetamine salts conversion. The manufacturer labeling and clinical pharmacology literature suggest that 30 mg lisdexamfetamine yields approximately 8.9 mg d-amphetamine at steady state, while 20 mg Adderall XR provides approximately 12.5 mg total amphetamine (15% l-amphetamine, 85% d-amphetamine by activity) [23]. A conservative clinical approach starts the new agent at a moderate dose and titrates over two to four weeks, rather than attempting a milligram-per-milligram substitution.

Monitoring After the Switch

Prescribers should reassess ADHD symptom control and adverse effects at four weeks post-switch using a validated rating scale such as the ADHD-RS-5 or ASRS-v1.1. Blood pressure and heart rate should be rechecked at the same visit [24].

Practical Prescribing and Patient Access Checklist

Before writing or filling either prescription, patients and clinicians should confirm five things.

1. Formulary tier: Call the insurance plan or check the online formulary to verify cost-share for generic lisdexamfetamine and generic Adderall XR at the dispensing pharmacy.
2. Pharmacy stock: Call the pharmacy before sending the Rx. Because both are Schedule II, transferred prescriptions are complex; confirming stock first saves time.
3. Telehealth prescribing deadline: If receiving care via telehealth, confirm the provider's DEA registration covers your state and verify continuity of care before December 31, 2025 [15].
4. Manufacturer coupon eligibility: Check whether the Takeda Vyvanse Savings Card applies (commercial insurance only; not Medicare/Medicaid).
5. Shortage alternatives: If neither is available, ask the prescriber about dextroamphetamine extended-release (Dexedrine Spansules) or methylphenidate-based alternatives as a temporary bridge, both of which remain Schedule II but have different supply chains.

Frequently Asked Questions